Prospective, Open-Label Study of Andexanet Alfa in Patients Receiving a Factor Xa Inhibitor Who Have Acute Major Bleeding (ANNEXA-4)

Trial Profile

Prospective, Open-Label Study of Andexanet Alfa in Patients Receiving a Factor Xa Inhibitor Who Have Acute Major Bleeding (ANNEXA-4)

Recruiting
Phase of Trial: Phase III/IV

Latest Information Update: 22 Sep 2018

At a glance

  • Drugs Andexanet alfa (Primary)
  • Indications Haemorrhage
  • Focus Registrational; Therapeutic Use
  • Acronyms ANNEXA-4
  • Sponsors Portola Pharmaceuticals
  • Most Recent Events

    • 05 Sep 2018 This trial has been completed in France.
    • 16 Aug 2018 Planned number of patients changed from 350 to 500.
    • 24 Jul 2018 Results (from ANNEXA-A, ANNEXA-R and ANNEXA-4) published in the American Journal of Medicine
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top